Sage and Bio­gen build out case for de­pres­sion drug as it pass­es PhI­II test in post­par­tum women

Sage Ther­a­peu­tics and Bio­gen are con­tin­u­ing a march for­ward in the de­pres­sion space and have new da­ta that they hope will wow in­vestors and the FDA alike.

A Phase III study of zu­ra­nolone met all its pri­ma­ry and key sec­ondary end­points for treat­ing women with post­par­tum de­pres­sion (PPD). The drug is al­so be­ing de­vel­oped to treat ma­jor de­pres­sive dis­or­der (MDD).

Ac­cord­ing to the da­ta, women treat­ed with a 50 mg dose of zu­ra­nolone demon­strat­ed a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in de­pres­sive symp­toms af­ter two weeks, meet­ing the pri­ma­ry end­point. Re­searchers com­pared the changes in base­line to place­bo as mea­sured by the 17-item Hamil­ton Rat­ing Scale for De­pres­sion (HAMD-17) to­tal score.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER